Figure 1.
NQO1 C609T polymorphisms and pharmacokinetics. The plasma concentration wih mean ± SD, ng/mL. (A) AMR on day 4 in patients receiving AMR at a dose of 30 mg/m2. (B) AMR on day 4 in patients receiving AMR at a dose of 40 mg/m2. (C) AMR-OH on day 4 in patients receiving AMR at a dose of 30 mg/m2. (D) AMR-OH on day 4 in patients receiving AMR at a dose of 40 mg/m2. *Exhibited a tendency toward a relationship with NQO1 genotypes (B) P = 0.0947, (D) P = 0.066, respectively.
Note: *P < 0.1.